To define mechanisms by which polysaccharide capsules confer enhanced virulence on gram-negative bacteria, we examined the effect of the Escherichia coli capsule on complement fixation to the bacterial surface and on phagocytosis and killing of these bacteria by mouse macrophages and human polymorphonuclear leukocytes (PMN) and monocytes. When E. coli were attached to mouse macrophages with concanavalin A, the macrophages readily phagocytosed unencapsulated but not encapsulated bacteria even in the presence of fresh mouse serum; macrophages did not phagocytose encapsulated E. coli unless antibacterial or anti-Con A antibody was added. Similarly, when these bacteria were attached to human PMN with Con A, PMN ingested unencapsulated but not encapsulated E. coli. PMN phagocytosed and killed encapsulated serum-resistant E. coli only in the presence of both complement and antibacterial antibody; PMN phagocytosed and killed unencapsulated E. coli of the same strain in the presence of complement alone. Fluorescence microscopy showed that antibody had to be present for encapsulated but not unencapsulated E. coli to fix complement to its surface. To examine the role of the complement receptors of human PMN and monocytes in phagocytosis and killing of encapsulated E. coli, we used human and rabbit antibacterial immunoglobulin (Ig)M to fix complement to the bacteria. PMN and monocytes phagocytosed and killed encapsulated E. coli in the presence of both IgM and complement, but […] 82 IgG, PMN and monocytes required complement to effectively phagocytose and kill the E. coli.
A B S T R A C T To define mechanisms by which polysaccharide capsules confer enhanced virulence on gram-negative bacteria, we examined the effect of the Escherichia coli capsule on complement fixation to the bacterial surface and on phagocytosis and killing of these bacteria by mouse macrophages and human polymorphonuclear leukocytes (PMN) andl mnonocytes. When E. coli were attached to mouse macrophages with concanavalin A, the macrophages readily phagocytosed unencapsulated but not encapsulated bacteria even in the presence of fresh mouse serum; macrophages did not phagocytose encapsulated E. coli unless antibacterial or anti-Con A antibody was added. Similarly, when these bacteria were attached to human PMN with Con A, PMN ingested unencapsulated but not encapsulated E. coli. PMN phagocytosed and killed encapsulated serumresistant E. coli only in the presence of both complement and antibacterial antibody; PMN phagocytosed and killed unencapsulated E. coli of the same strain in the presence of complement alone. Fluorescence microscopy showed that antibody had to be present for encapsulated but not unencapsulated E. coli to fix complement to its surface.
To examine the role of the complement receptors of human PMN and monocytes in phagocytosis and killing ofencapsulated E. coli, we used human and rabbit antibacterial immunoglobulin (Ig)M to fix complement to the bacteria. PMN and monocytes phagocytosed and killed encapsulated E. coli in the presence of both IgM and complement, but not in the presence of either serum opsonin alone. In the presence of antibacterial INTRODUCTION For many bacterial species, the presence of a capsule has been identified as a critical determinant of virulence. For some, such as Escherichia coli, the degree of virulence is a function of both the size and composition of the capsule (1) . In experimental animals, encapsulated forms are more virulent than unencapsulated forms (2, 3) , and the degree of virulence is proportional to the quantity of capsular (K) antigen expressed on the bacterial surface (4) .
Most E. coli isolated from human infections are encapsulated (1, 5) . E. coli isolated from the urine of patients with pyelonephritis contain especially large amounts of capsular antigen (6) (7) (8) , and certain capsular serotypes, most notably Kl, predominate in these patients and in infants with E. coli meningitis (6, (9) (10) (11) .
In view of the importance of encapsulated E. coli and other encapsulated gram-negative bacteria as hu-duces the bactericidal effects of serum on E. coli and enhances the ability of this organism to resist phagocytosis (2, 4, 12, 13) . Others have shown that anticapsular antibody has a protective effect on rabbits and mice inoculated with encapsulated E. coli (14, 15) . These findings suggested to us that the capsule may alter the binding of complement to the E. coli surface.
Complement activation by E. coli and other gramnegative bacteria has been examined almost exclusively in unencapsulated strains. Thus, although it is known that unencapsulated E. coli fix complement via the alternative complement pathway (16) (17) (18) , virtually nothing is known about complement fixation or consumption by encapsulated E. coli. Similarly, studies of phagocytosis ofE. coli have focused on unencapsulated E. coli, particularly the laboratory-adapted and rough E. coli K12 strain, or on encapsulated E. coli that have been heat-killed and thereby have had their capsule destroyed. Such studies may not be relevant to the in vivo situation where pathogenic bacteria are encapsulated.
We undertook this study to define the mechanisms by which capsules promote virulence of gram-negative bacteria. In our studies, we used an encapsulated E. coli strain (serotype 09:K29:H-) originally isolated from human peritoneum (19) , and unencapsulated mutant strains bearing the 09 somatic antigens. We chose these strains because the chemical structures of the 09 siomatic (20) and K29 capsulatr (21) antigens have been determined and both are composed of repeating polysaccharide subunits containing the specific carbohydrate-combining site (22) for the plant lectin concanavalin A (Con A).' The presence of Con A binding sites on the bacteria allowed us to attach the bacteria to the surface of mouse and human leukocytes with this lectin and study bacteria-phagocyte interactions in the absence of the two major serum opsonins, antibody and complement. We shall demonstrate that the presence of a capsule markedly alters the interactions of E. coli with serum complement and with the surface of phagocytic leukocytes. Additionally, we shall characterize the roles of antibody and complement in phagocytosis and killing of encapsulated E. coli by phagocytic leukocytes.
METHODS
Reagents. Con A, three times crystallized and lyophilized (Miles-Yeda Ltd., Kankakee, Ill.); a-methyl-D-mannopyrano-IAbbreviations used in this paper: Abs S, human serum absorbed with E. coli K+ and K-; AD, agglutinating dose; CFU, colony-forming units; Con Media. Dulbecco's phosphate-buffered saline with Ca++ and Mg"+ ions (PBS) (23); Hanks' balanced salt solution (HBSS) 10 x (Grand Island Biological Co., Grand Island, N. Y.), adjusted to pH 7.4; PBS without Ca++ and Mg++ (PD); tryptic soy broth (TSB) (Difco Laboratories, Detroit, Mich.); minimal essential medium without glucose (24) .
Polymorphonuclear leukocytes (PMN). Blood from a single healthy donor (type AB+) was collected in a heparinized syringe, mixed 1:1 with dextran 6% wt/vol in 0.9% saline (Dextran 75, Abbott Laboratories, Chicago, Ill.), and sedimented at 24°C. PMN were separated from the leukocyterich supernate by centrifugation over a discontinuous gradient of Ficoll (Ficoll 400, Pharmacia Fine Chemicals, Piscataway, N. J.) and sodium diatrizoate (Hypaque sodium 50%, Winthrop Laboratories, New York) as described (25) . The granulocyte-rich fraction thus obtained was washed twice in PBS (40C) by centrifugation at 200 g for 10 min at 4°C after which residual erythrocytes were lysed by a 1-min exposure to 0.2% saline. Isotonicity was rapidly restored with 1.6% saline, and the cells (>99% PMN) were pelleted, resuspended in HBSS, counted in an improved Neubauer Chamber (Clay Adams, Div. Becton, Dickinson & Co., Parsippany, N. J.), stored at 0°C at the required concentration and used within 30 min of purification. Viability was >99% by the criterion of trypan blue exclusion.
Human monocytes. Heparinized blood was diluted 1:1 in 0.9% saline and the mononuclear fraction obtained by centrifugation at 800 g for 30 min at 240C over a Ficoll-sodium diatrizoate solution (Ficoll-Paque, Pharmacia Fine Chemicals) as described (26) . The mononuclear cells were collected, washed, purified of erythrocytes, and resuspended in HBSS exactly as described for PMN. A sample of the suspension was cytocentrifuged (Cytospin, Shandron Southern Instruments Inc., Sewickley, Pa.) and stained. A differential cell count was done in each experiment, and the monocyte concentration was adjusted to the required concentration; the cell population (>99% viable by trypan blue exclusion) contained -1.5% PMN, 40% monocytes, and 58.5% lymphocytes.
Mouse peritoneal inacrophages. Resident and thioglycollate-elicited mouse peritoneal macrophages were harvested and cultured on 13-mm Diam glass coverslips as described (27 (28) . For stock cultures, a highly mucoid E. coli K+, an E. coli K-, or an E. coli 09:K9-:H12 colony was grown in TSB at 37°C on a rotatory shaker to mid-log phase (OD of 0.300 at 540 nm measured in a Coleman 44 model spectrophotometer [Perkin-Elmer Corp., Norwalk, Conn.]) and the culture stored at -70°C in 10% glycerol. As needed, cultures were thawed and cultured on TSB agar. An appropriate colony was picked, grown up on TSB agar, and held at room temperature for 2-7 d. 14-18 h before an experiment, an appropriate colony was again picked and grown up on TSB agar at 37°C; a standard inoculum from this growth was suspended in 150 ml of TSB and grown at 37°C to an OD of 0.300 at 540 nm. The bacteria were then collected by cenitrifugation at 1,500g for 10 min at 4°C, washed twice, and resuspended in PBS (4°C) to the required concentration, stored at 40C, and used within 1 h; there was no loss in colony-forming uinits (CFU) on storage for at least 4 h. A 1% suspension of E. coli K+ adjusted to an OD of 0.410 at 540 nm yielded 2.65 x 108 CFU/ml; 0.2% suspensions of E. coli K-and E. coli 09:K9-:H12 adjusted to an OD of 0.510 at 540 nm yielded 2.5 and 2.8 x 108 CFU/ml, respectively.
Hutmtizan sera. Venous blood was clotted in siliconized glass test tubes, stored for 1 h at room temperature and an additional 1 h at 40C, and the normal serum (NS) separated and stored at -700C. Complement activity was inactivated by heating serum at 56°C for 30 min just before use. Absorbed serum was prepared by successively incubating 30 ml of a 1:1 mixture of NS with PD three times with fresh batches of 1011 E. coli K+ and/or K-on a gyratory shaker at 40C for 1 h; the bacteria had been grown to mid-log phase, washed in PD, and pelleted by centrifugation. Absorbed serum was separated from the bacteria by centrifugation, filtered (0.45 itm Millipore filters; Millipore Corp., Bedford, Mass.), and stored at -700C. Complement activity: classic pathway. Hemolytic activity for antibody-coated sheep erythrocytes (RBC) in normal and absorbed human serum was measured as described (29) . Normal human serum had 365 CH50 U/ml, serum absorbed with E. coli K+ had 200 CH50 U/ml, serum absorbed with E. coli K-had 200 CH56 U/ml, and serum absorbed with both organisms had 250 CH50 U/ml. Complement activity: alternative pathway. Hemolytic activity of normal and absorbed sera for rabbit RBC was measured by a modification of the method of Platts-Mills and Ishizaka (30) . A standard hemolysis curve (percentage RBC on ordinate; OD units on abscissa) was generated by incubating 200 ,lI of a suspension of rabbit RBC in concentrations ranging from 0 to 1% vol/vol in EGTA buffer (30) with 400 ,ul of water for 5 min at 4°C, adding 2.5 ml of EGTA buffer (4°C), centrifuging, and determining the OD of the supernate at 412 nm on a Coleman 44 spectrophotometer. Sera were assayed by incubating 200 Al of 1% rabbit RBC with 0-400 ,u of serum in EGTA buffer for 30 min at 370C, stopping the reaction by adding 2.5 ml of EGTA buffer (4°C), centrifuging, and determining the OD of the supernate. The percentage ofhemolysis (y) was determined from the standard hemolysis curve, and the 50% hemolytic titer was obtained graphically on log-log paper by plotting on the x-axis the amount of serum added, and on the y-axis the ratio y/100-y; 1,000 divided by the amount of serumil in microliters giving 50% hemolysis (x intercept) yielded CH50 alternative pathway hemolytic activity (after Mayer) (29) . Measured in this way, normiial serum had 10.9 CH50 U/nml, serum] absorbed with E. coli K+ had 9.7 CH50 U/mI11, serum] absorbed with E. coli K-ha(l 10.5 CH50 U/ml, and( serum absorbed with both organisms had 5.1 CH50 U/ml. Preparation of IgM and IgG fractions of human serum. Serum was dialized against 0.2 M NaCl, 0.1 M Tris-HCl, and 0.02% azide, pH 8.0, and IgM and IgG were separated on a Sephadex G-200 columlln (Pharmnacia Finie Chemiiicals) as described (29) . Appropriate fractions were concentrated 100-fold by pervaporation with a collo(lioni bag apparatus (Schleicher and Schuell, Inc., Keenie, N. H.) and( teste(d for IgM and IgG by double immunodiffusion using heavy chain-specific antisera. Fractions free of cross-contamination were combined and designated IgM or IgG fractions; these fractions were adjusted to roughly the same volume as the serumil sample from which they were obtained, dialyzed three times against 100-fold volumes of PBS, filtered (0.45 ,tum Millipore filter), again demiionistrated free of cross-contamninants b, dloul)le illimuinodiffusion, and stored at -70'C. Examination of the IgM fraction by immunoelectrophoresis (31) confirmed the absence of IgG. The protein concentrations of the human IgM and IgG fractions were 0.05 and 4.4 mg/ml, respectively (32) .
Rabbit anti-E. coli K' IgM and lgG. New Zealand white rabbits injected intravenously at 4-d intervals for 12 d with increasing amounts of an E. coli K+ vaccine prepared as described (33) yielded antiserum with a high titer of both IgM and IgG antibody. IgM and IgG fractions were separated by Sephadex G-200 chromatography, demonstrated free of cross-contamination, and stored as described above for human serum. The protein concentrations of the rabbit IgM and IgG fractions were 0.8 and 6.1 mg/ml, respectively. 1 ml of a 1% suispension of E. coli K+ in PBS was aggluitniiated by 25 ,ul of IgM or 75 ,l of IgG.
Protein A absorption of rabbit IgM. The rabbit IgM fraction was absorbed with protein A to assure complete removal of IgG by diluting 350 ,ul of the IgM fraction 1:9 with PBS and absorbing it twice at 4°C for 1 h with 0.1 -nl of gel containing 58 mg of dry protein A-Sepharose CL-4B (Pharmacia Fine Chemicals). This amount of gel was in excess of that require(d to remove all the IgG from 350 Al of a 1:9 dilution of the rabbit IgG fraction.
Fluorescence microscopy of complement-coated bacteria. 3 x 106 mid-log phase bacteria were incubated for 15 min at 37°C with 600 ,tl of 25% normal or absorbed serum in PBS, washed twice with PBS, incubated for 10 min at 37°C with a mixture containing 20 ,ul of rhodamine-conjugated goat antihuman C3 IgG and 80 ,ul PBS, washed again, resuspended in 100 ul of PBS, and examined with a Zeiss Fluorescent Photomicroscope III (Carl Zeiss, Inc., New York). IgM-and IgG-mediated complement fixation to the surface of the E. coli K+ was determined similarly, except in the initial step 1.5 x 106 bacteria were incubated with 0-60 ,ud of human IgM or IgG fraction in a total volume of 300 ,ul of 10% absorbed serum.
Attachment of bacteria to phagocytes with Con A. E. coli were attached to mouse macrophages with Con A by washing the macrophages three times with PBS (4°C), incubating them with 125 ,ug Con A/ml PBS for 30 min at 4°C, again washing them three times with PBS (4°C), and incubating them for 45 min at4°C with 1 ml ofa 2% suspension ofencapsulated E. coli 09:K29:H-(E. coli K+) or a 1% suspension of unencapsulated E. coli 09:K9-:H12 for 45 min at 4°C. E. coli were attached to PMN with Con A by incubating a 1% suspension of E. coli K+ or E. coli 09:K9-:H12 with subagglutinating amounts of Con A (250 ,tg/ml PBS for E. coli K+ and 8 PMN killing assay. In all killing assays, reactants (total volume 900 ,l) were added to plastic tubes in an ice water bath; the tubes were then gassed with 5% C02-95% air so that the pH was 7.4 as judged by the color of the phenol red indicator dye, capped, sealed with Parafilm (American Can Co., Greenwich, Conn.), and incubated at 37°C on a gyratory shaker at 240 rpm. In most experiments, human imnmunoglobulin, autologous serum (normal, absorbed, or heat inactivated), 5 x 106 PMN in 500 u1 HBSS, or the various controls for these reactants, and 0.5 or 1 x 106 bacteria in 100 ,u of PBS, were added in that order. In experiments involving rabbit immunoglobulin, the immunoglobulin and bacteria were added first and incubated at room temperature for 10 min before other reactants were added as above. A separate tube was used for each time point; thus tubes were not opened until the end of the incubation. At that time, the tubes were placed in an ice water bath to stop the reaction, and the contents were sonicated under sterile conditions with an amount of energy sufficient to lyse leukocytes completely (as measured by phase-contrast microscopy) but not to reduce bacterial CFU. To determine the number of CFU, the contents of each tube were serially diluted in PBS (4°C), spread onto 100 x 15-mm TSB agar plates using a glass spreader and a rotating wheel (Rota-Plate, Fisher Scientific Co., Pittsburgh, Pa.), incubated overnight at 37°C, and colonies counted manually with a colony counter (New Brunswick Scientific Co., Inc., Edison. N. J.). Monocyte killing assay. The assay was identical to the above except that mononuclear cells rather than PMN were added to the reaction mixture. On the basis of the differential cell count, 2.5 x 106 monocytes were incubated with 5 x 105 E. coli K+ (monocyte:bacteria ratio of 5: 1). PMN phagocytosis assay 1: PMN in monolayer. PMN (1.25 x 105 in 75 /l HBSS) were allowed to attach to 13-mm Diam glass coverslips in 16-mm Diam culture wells (Costar Data Packaging, Cambridge, Mass.) for 15 min at 37°C under 5% C02-95% air atmosphere after which the various serum preparations and 6.25 x 105 bacteria in a total volumiie of 300 gl were added to each well. The wells were gassed with a 5% CO2-95% air mixture, the entire 24-well unit sealed with Parafilm, and the unit incubated for 20 min at 37°C on a gyratory shaker at 140 rpm. Each coverslip was then washed with ice-cold PBS, fixed in 2.5% glutaraldehyde in PD, mounted on a glass slide, and examined by phase-contrast microscopy; over 100 PMN in random fields were examined, and the percentage of PMN with vacuoles containing bacteria determined.
PMN phagocytosis assay II: PMN in suspension. This assay, which allowed accurate counts of ingested bacteria, was set up exactly as the PMN killing assay involving rabbit immunoglobulin except that a total of 107 E. coli K+ were incubated with 2.5 x 106 PMN (bacteria:PMN ratio of 4:1) for 30 min; afterward, 100-,ul samples from each tube were cytocentrifuged onto glass slides. The cells were fixed and stained with Diff-Quik Fixative and Solutions (Harleco, American Hospital Supply Corp., Gibbstown, N. J.) and the percentage of PMN with cell-associated bacteria and the number of bacteria per ingesting PMN determined microscopically. As 94% of PMN with cell-associated bacteria had at least one clearly intracellular bacterium by the criteria that the bac-terium was in a vacuole and/or partially digested and at least 79% of all cell-associated bacteria were clearly intracellular by these criteria, all cell-associated bacteria are tabulated as phagocytosed bacteria (see Results).
Monocyte phagocytosis assay. This assay was identical to PMN phagocytosis assay II except that mononuclear cells rather than PMN were added to the reaction mixture. On the basis of the differential cell count, 106 monocytes were incubated with 107E. coli K+ (bacteria:monocyte ratio of 10:1).
RESULTS
The influence of the capsule on ingestion of E. coli attached to phagocytes with Con A and the role of antibody and complement in ingestion ofencapsulated and unencapsulated strains. To examine the influence of the capsule on the attachment and ingestion stages of phagocytosis, we first asked whether ingestion automatically follows attachment of E. coli to the surface of phagocytic leukocytes or whether antibody and complement are additionally required. At the same time, we asked whether the presence of a capsule influences the fate of bacteria once they are attached.
To answer these questions, we required a method of attaching E. coli to phagocytes without antibody and complement. For this purpose, we used Con A, as described in NMethods; over 98% of macrophages and PMN had adherent bacteria, usually 10-20 bacteria/ PMN and 20-50/macrophage. Encapsulated E. coli 09:K29:H-(E. coli K+) bound to the surfaces of resident or thioglycollate-elicited mouse peritoneal macrophages or human PMN with Con A were not ingested on incubation of the bacterialeukocyte complexes in PBS or minimal essential medium without glucose at 37°C for 1-3 h; glucose-free medium was used because glucose is a competitive inhibitor of Con A and promotes the release of bacteria from the leukocyte surface. In fact, these bacteria multiplied on the sturface of the phagocytes. After 1-3 h incubation, these E. coli were eluted from the phagocyte surface with 100 mM aMM, a competitive inhibitor of Con A (Fig. 1) . In contrast, unencapsulated E. coli 09:K9-:H12 bound to the phagocytes with Con A were ingested by >95% of the phagocytes on incubation in PBS or minimal essential mediuim without glucose at 37°C for 1-3 h.
Other experiments confirmed that Con A does not promote phagoeytosis of encapsulated E. coli. We observed no ingestion when we treated E. coli-macrophage complexes (formed as described in Methods or by coating the bacteria w\ith a subagglutinating dose of Con A anld incub)ating themii wvith macrophages for 30 min at 4°C) wNith excess Coni A (125-250 ,.g/mnl) before (45 min at 4°C) or during the 37°C incubation.
Encapsulated E. coli were ingested by >95% of macrophages when 5% rabbit anti-E. coli K+ antiserum or 5% goat anti-Con A antiserum was added to the EPscherich ia coli Capsule Itifluienice oni Cornmplenent Fixaitio)1iand Pha(igocytosis media containing the complexes of resident or thioglycollate-elicited macrophages and Con A-coated E. coli. However, 10-20% fresh mouse serum from nonimmune mice (a source of complement but not antibody) did not induce ingestion of these bacteria.
In control experiments without Con A, encapsulated E. coli were not attached or ingested when incubated with resident or thioglycollate-elicited macrophages at 37°C for 1 h in the presence or absence of 10% fresh mouse serum. In contrast, unencapsulated E. coli 09: K9-:H12 were attached and ingested in medium containing fresh mouse serum, but not in serum-free medium.
We derived three conclusions from these experiments: (a) attachment of unencapsulated E. coli to the surface of a phagocyte is sufficient to induce ingestion of the unencapsulated bacteria; (b) attachment of encapsulated E. coli is insufficient to induce ingestion of these bacteria. Serum ligands, in this instance antibodies to bacterial surface antigens or to Con A on the bacterial surface, are required to promote phagocytosis; (c) in the absence of antibody, fresh mouse serum (a source of complement) promotes attachment and subsequently ingestion of unencapsulated E. coli, but is unable to promote either attachment or ingestion of encapsulated E. coli.
The experiments with fresh mouse serum strongly suggested that unencapsulated but not encapsulated E. coli fix complement in the absence of antibody and consequently are phagocytosed by phagocytes in the absence ofantibody. To test this hypothesis, we studied phagocytosis and killing of an encapsulated E. coli (E. coli K+) and an unencapsulated mutant (E. coli K-) of the same strain by human PMN and monocytes.
Killing of encapsulated and unencapsulated E. coli by human PMN in the presence of normal human serum. To determine the optimal ratio of PMN: bacteria for in vitro killing, we incubated E. coli K+ and K-with 5 x 106 PMN in 10% autologous normal human serum at 37°C for 1 h so that the ratio of PMN: bacteria ranged from 0.3:1 to 37.5:1. Killing occurred only in the presence of PMN. A 2-log reduction in CFU was obtained independent of the ratio of PMN:bacteria and of the status of encapsulation.
To study the kinetics of killing, we incubated 5 x 105 E. coli K+ or Kwith 5 x 106 PMN (PMN:bacteria ratio of 10:1) in 10% normal serum at 37°C for periods ranging from 0 to 120 min. Bacteria were killed only in 86 M. A. Horwitz and S. C. Silverstein the presence of both PMN and serum (Fig. 2) . Maximal killing was achieved by 60 min of incubation, and most or all of this occurred in the first 30 min. The rate of killing of encapsulated E. coli was similar to that of inencapsulated E. coli.
To study the effect of the concentration of normal serum on PMN killing, we incubated 5 x 105 E. coli K+ or K-with 5 x 106 PMN at 37°C for 1 h in medium containing 0-20% normal serum. With low serum concentrations (0.1 and 1%), significant (1 log) killing of the E. coli K-straini occurred but there wvas no killing of the E. coli K+ straini. \Vith higher concentrations of serum (5, 10, and 20%), significant killing (2-2.5 logs) of both E. coli K+ and K-strains occurred. Maximal killing ofboth strains occurred with 10 and 20% serum.
Roles of antibody and complement in the killing of etLcapsulatecl (10(1 uneflcaIpsullated E. coli by PMIN.
To examine the role of complement in the absence of antibody in the killing of E. coli by PMN, we absorbed normal human serum with E. coli K+ and K-. To grossly compensate for the 31% reduction in classic and 52% reduction in alternative complement pathway activities that occurred with absorption of the serum, we increased the concentration ofabsorbed serum from 10 to 15% in some samples. Heat-inactivated normal human serum served as a source of antibody. Several lines of evidence, described in later sections of this paper, confirmed that the human serum used in these studies contained antibodies directed against E. coli K+. PMN were unable to kill E. coli K+ or K-in the presence of heat-inactivated serum (Fig. 3 ). In the presence of absorbed serum (as a complement source), PMN readily killed E. coli K-(2 logs) but were unable to kill E. coli K+. However, PMN killed E. coli K+ in the presence of normal serum. We conducted these experiments with a PMN:bacteria ratio of 5:1. WVe obtained similar results with a PMN:bacteria ratio of 50:1 (5 x 106 PMN: 105 bacteria). Thus, the inability of PMN to kill E. coli K+ in the presence of absorbed serum was not a consequence of an inadequate ratio of PMN: bacteria.
We derived two important conclusions from the results of these experiments: (a) complement is required for the efficient killing of E. coli K+ and K-by PMN; (b) in the presence of complement, antibody is required to promote killing of encapsulated but not unencapsulated E. coli by PMN.
In other experiments, we determined that adequate levels ofboth antibody and complement are required to achieve maximal killing ofE. coli K+. With the antibody level held constant, PMN did not kill E. coli K+ significantly with 0.1-1% absorbed serum but killed them maximally (3 logs) with 5-10% absorbed serum (Fig.  4A ). Conversely, with the complement level held constant, PMN did not kill E. coli K+ with 0-0.1% heatinactivated serum, but killed them significantly (1 log with 1% and maximally (3 logs) with 5% heat-inactivated serum (Fig. 4B) . Control experiments showed that in the absence of PMN neither E. coli K+ nor K-were killed, even when a 50% concentration of normal serum was used. Thus it seemed likely that the differences in serum requirements for PMN killing of E. coli K+ and K-reflected differences in requirements for phagocytosis. Roles with antibody and complement, but PMN did not ingest E. coli K+. Thus, the requirements for PMN phagocytosis of E. coli K+ and K-precisely mirrored the requirements for PMN killing of these bacteria: antibody and complement were required for phagocytosis of encapsulated E. coli, whereas complement alone sufficed for phagocytosis of unencapsulated E. coli. The simplest explanation for the differences in requirements between the two organisms was that antibody was required for fixation of complement onto the encapsulated but not the unencapsulated E. coli.
Antibody is required to fix complement to encapsulated but not to unencapsulated E. coli. To establish the requirements for complement binding to E. coli K+ or K-, we incubated these bacteria with absorbed serum (complement) or whole normal serum (complement and antibody) and then with rhodamine-conjugated goat antihuman C3 IgG and examined them by fluoresence microscopy. After incubation in normal serum (antibody and complement), both E. coli K+ and K-bound complement as evidenced by very bright fluorescence of the bacteria (Fig. 5 ). With complement alone, the encapsulated bacteria exhibited no fluorescence but the unencapsulated bacteria fluoresced brikhtly. Neither type of bacteria exhibited fluorescence when incubated with heat-inactivated normal or heat-inactivated absorbed serum.
Thus, antibody is required for binding complement to encapsulated but not to unencapsulated E. coli. The serum requirements for complement binding are identical to those for phagocytosis and killing by PMN.
In other words, unless the bacteria are coated with complement, PMN can neither phagocytose nor kill them efficiently. Role of the coiiiplemnent and imnutnolobulin receptors in killing (iand phaocijto.sis of enicapstulated E. coli byl hum ) an PAIN. Having determined that phagocytosis and killing of the encapsulated E. coli were dependent upon both antibody and complement, we now sought to deterniine the roles of the C3 and Fe receptors of human PMN in this process. To study C3 receptor function independent of the Fc receptor, we used IgM to fix complement to the bacterial surface. Fc receptors of human PMN do not bind IgM. To study Fc receptor function independent of the C3 receptor, we used IgG in the absence of complement. We obtained human IgM and IgG free of detectable contamination with each other as described in Methods. By fluorescence microscopy, we confirmed that both immunoglobulin preparations promoted the binding of complement to E. coli K+ in a dose-dependent fashion, i.e., fluorescence appeared and then increased as the amount of immunoglobulin added was increased from 0 to 60 ,1 (see Methods).
Both the IgM and IgG fractions efficiently promoted killing of E. coli K+ by PMN (Fig. 6 ). When added together, the two immunoglobulins acted synergistically; when 9 ,ul of IgG was added to 90 gl of IgM, killing was enhanced by an additional log over that seen with 90 ,ul of IgM alone. Bacterial killing was similarly augmented when 9 ,ul of IgM was added to 90 gl of IgG in the same assay. The amount of each immunoglobulin preparation required for significant bacterial killing (90 and 180 ,AI) was roughly equivalent to that present in 10 (90 ,ul) and 20% (180 ul) normal serum, respectively. Control experiments showed that in the absence of complement neither human immunoglobulin fraction promoted killing of E. coli K+ by PMN.
The capacity of IgM and complement to promote killing of E. coli K+ by PMN indicates that these bacteria are phagocytosed via PMN complement receptors. This finding was surprising in view of the report of Ehlenberger and Nussenzweig (34) that the C3 receptor of PMN mediates attachment but not phagocytosis of complement-coated sheep RBC, and that Fc receptor function is required for efficient phagocytosis of sheep RBC. To confirm our results, we repeated the killing experiments with high titer rabbit anti-E. coli K+ IgM and IgG. By double immunodiffusion against goat anti-rabbit IgG, the undiluted rabbit IgM fraction gave no precipitin line, whereas a 1:99 dilution of the IgG fraction yielded a clear precipitin line. To eliminate the possibility that trace amounts of IgG might be contaminating the IgM preparation, we absorbed the rabbit IgM fraction twice with an amount of protein A-Sepharose in excess of that sufficient to remove all opsonic activity from an equal volume of the IgG fraction of this antiserum, as measured by the bacterial killing assay, and all traces of IgG from the same IgG fraction as measured by double immunodiffusion; protein A complexes with >97% of rabbit IgG (35) .
In the presence of absorbed serum as a complement source and either rabbit IgG or protein A-absorbed rabbit IgM, PMN killed E. coli K+ (Table II) . With complement and both IgM and IgG, PMN killed significantly more E. coli K+ than with either immunoglobulin alone. Without complement, PMN killed E. coli K+ with IgG but not IgM; under these ,pircumstances, killing occurred only at the higher dose of IgG employed (0.04 agglutinating dose). These results confirmed that PMN kill E. coli K+ in the presence of anti-E. coli K+ IgM and complement; IgG is not required. With IgG, PMN kill E. coli K+ more efficiently in the presence of complement than in its absence.
To confirm that PMN killing of bacteria with rabbit immunoglobulin was a consequence of phagocytosis of E. coli K+, we measured ingestion of these bacteria by PMN using the PMN phagocytosis assay II de-scribed in Methods. As expected, in the presence of absorbed serum, we found an excellent correlation between the capacity of rabbit IgG or IgM to promote phagocytosis (Table III) and their capacity to promote killing (Table II) of E. coli K+ by PMN. Phagocytosis and killing of E. coli K+ by human blood monocytes. To determine the opsonic requirements for phagocytosis and killing of E. coli K+ by human blood monocytes, we performed experiments similar to those described above for PMN. As shown in Table IV and Fig. 7 , the serum requirements for phagocytosis and killing of E. coli K+ by monocytes were similar to those observed for PMN. Monocytes phagocytosed and killed E. coli K+ efficiently only in the presence of complement and antibody (either IgM or IgG).
In obtaining monocytes, we found by chance that if the blood were dextran-sedimented before application to Ficoll-sodium diatrizoate (instead of being applied directly), the mononuclear fraction thus obtained was heavily contamiiniiatedl with PMN and consisted on the average of 40% monocytes, 36% PMN, and 24% lymphocytes. This allowed a comparison of the phagocytic capabilities of PMN and monocytes obtained in comparable numbers under identical conditions. When we reacted 4 x 106 E. coli K+ with a mixture containing -106 monocytes and 106 PMN under the same conditions as in Tables III and IV, we found that PMN were strikingly superior to monocytes in phagocytic capability. The phagocytic indices for PMN and monocytes were 620 and 89, respectively, in the presence of IgM and complement, and 370 and 31, respectively, in the presence of IgG and complement; in these preparations, nearly all the bacteria were in PMN. However, with IgG or heat-inactivated antiserum alone, we found that monocytes and PMN had comparably low phagocytic capacities (indices s 40). This suggested that the complement receptor of the PMN is more efficient than the complement receptor of the monocyte in promoting phagocytosis of complement-coated encapsulated bacteria, but that the Fc receptors of the two phagocytes are comparably efficient.
DISCUSSION
The surfaces of most unencapsulated gram-negative bacteria are rich in lipopolysaccharide. In the absence of antibody, it is presumably the interaction of this surface with complement components that activates the complement pathway and leads to the deposition of complement onto the bacterial surface; lipopolysaccharide has been shown capable of fixing complement without antibody (36 (34) . We cannot explain these differences in the response of PMN and monocytes to complement-coated sheep RBC and encapsulated E. coli.
The relative roles of complement and antibody in promoting phagocytosis of bacteria coated with these ligands are of more than academic interest. Our results indicate that a host lacking specific IgM or IgG antibacterial antibody might be susceptible to infection with encapsulated but not unencapsulated bacteria. Early in the course of an infection, IgM may be the only antibacterial antibody present. Inasmuch as PMN and monocytes have no IgM receptors, complement would be the only serum ligand available to promote clearance of encapsulated bacteria.
Three points should be taken into account in studying complement binding to bacteria. First, the state of encapsulation of the bacteria is an important determinant of their capacity to bind complement. The amount of capsular material present may vary with different culture conditions. Second, serum must be thoroughly absorbed to remove natural and cross-reacting antibody from "nonimmune" serum; otherwise, a requirement for antibody for complement fixation may be missed. Third, serum must be absorbed with both encapsulated and unencapsulated bacteria to remove all antibacterial antibody. Absorption with encapsulated blacteria alone does not effectively remove antibody to subcapsular surface antigens such as the somatic 0 antigen. In studies whose details are not included here, we found that serum absorbed with only E. coli K+ promoted phagocytosis and killing of E. coli K.+ Serum absorbed with both E. coli K+ and K-was inactive in the absence of added antibody (Figs. 3, 4 , 6, and 7; Tables I-IV).
These findings suggest that antibodies directed against somatic antigens can react with encapsulated E. coli and promote the binding of complement to their surface. The reports of Kaijser et al. (15) , and Kaijser and Olling (14) that antibody to the somatic 0 antigen of encapsulated E. coli protected animals against infection with these bacteria are consistent with this view. On the other hand, a large capsule may render subcapsular surface antigens totally inaccessible to antibody, thus preventing antibody to the 0 antigen from mediating complemenit fixation; Howard and Glynn (4) reported that anti-OK antibody but not ainti-O antilbody enhanced the clearance of initravenously injected encapsulated E. coli.
Complement consumption by bacteria may not be synonymous with complement binding to the bacteria.
Bacteria release substances such as proteases and endotoxin that cause complement consumption in the fluid phase (38) . Similarly, complement fixation to isolated bacterial structures (e.g., cell walls, cell membranes, peptidoglycan) may not be relevant to the in vivo situation where anatomical barriers such as a capsule may limit access of complement components to these structures in the intact bacterium. For these reasons, we studied complement binding to intact bacteria directly by using rhodamine-conjugated antihuman C3 IgG.
The fluorescent antibody assay for complement fixation described in this paper is a simple, rapid, sensitive, reliable, and inexpensive technique for determining whether antibody is required to fix the third component of complement to the surface of any bacterium of interest. To screen a particular bacterium with this assay, one requires only appropriately absorbed serum. Because antibody is required for complement binding and phagocytosis of encapsulated E. coli, determining whether or not antibody is required to bind complement to other bacterial species may provide insight into requirements for antibody in host defense against them.
On the basis of our findings, we postulate the following model for the interaction of bacteria (except intracellular parasites) with the host humoral and cellular defense systems. When unencapsulated gramnegative bacteria encounter serum, their lipopolysaccharide-rich outer membrane promotes complement fixation to the bacterial surface. Consequently, the bacteria are either lysed by late-acting complement components or ingested and removed by phagocytic leukocytes. When encapsulated gram-negative bacteria encounter serum, complement is not fixed to the bacterial surface in the absence of specific antibacterial antibody. Consequently, encapsulated bacteria are resistant to complement lysis and phagocytosis. This may account, at least in part, for the enhanced pathogenicity of encapsulated gram-negative bacteria. If specific antibody is available, complement is bound and the encapsulated bacteria are either lysed or phagocytosed. This model may also apply to gram-positive bacteria. The capsules of gram-positive organisms are also important determinants of virulence; in the case of pneumococcus, the role of anticapsular antibodies in host defense has been recognized for a half century. The outer surface of the unencapsulated gram-positive bacteria, a cell wall containing peptidoglycan, has been shown to promote complement activation (39, 40) 
